Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Entamoeba histolytica | hypothetical protein, conserved | 0.1781 | 0.5 | 0.5 |
Schistosoma mansoni | sphingosine kinase A B | 0.1781 | 0.5 | 0.5 |
Mycobacterium ulcerans | hypothetical protein | 0.1781 | 0.5 | 0.5 |
Mycobacterium tuberculosis | Conserved protein | 0.1781 | 0.5 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.1781 | 0.5 | 0.5 |
Echinococcus multilocularis | sphingosine kinase 1 | 0.1781 | 0.5 | 0.5 |
Schistosoma mansoni | sphingoid long chain base kinase | 0.1781 | 0.5 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Activity (functional) | Anticonvulsant activity in Mus musculus (mouse) assessed as protection against 6 Hz psychomotor-induced clonic seizures at 100 mg/kg, i.p. measured at 0.25 hr relative to control | ChEMBL. | No reference | |
Activity (functional) | Anticonvulsant activity in Mus musculus (mouse) assessed as protection against 6 Hz psychomotor-induced clonic seizures at 100 mg/kg, ip measured at 2 hr relative to control | ChEMBL. | No reference | |
Activity (functional) | Anticonvulsant activity in Mus musculus (mouse) assessed as protection against 6 Hz psychomotor-induced clonic seizures at 100 mg/kg, i.p. measured at 4 hr relative to control | ChEMBL. | No reference | |
Activity (ADMET) | Neurotoxicity in Mus musculus (mouse) assessed as motor impairment at 100 mg/kg, ip measured at 1 hr by rotarod test relative to control | ChEMBL. | No reference | |
Activity (ADMET) | Neurotoxicity in Mus musculus (mouse) assessed as motor impairment at 100 mg/kg, ip measured at 0.5 hr by rotarod test relative to control | ChEMBL. | No reference | |
Activity (functional) | Anticonvulsant activity in Mus musculus (mouse) assessed as protection against maximal-electric shock-induced seizures at 30 to 300 mg/kg, ip measured at 0.5 hr | ChEMBL. | No reference | |
Activity (ADMET) | Neurotoxicity in Mus musculus (mouse) assessed as motor impairment at 100 mg/kg, ip measured at 4 hr by rotarod test relative to control | ChEMBL. | No reference | |
Activity (ADMET) | Neurotoxicity in Mus musculus (mouse) assessed as motor impairment at 100 mg/kg, ip measured at 0.25 hr by rotarod test relative to control | ChEMBL. | No reference | |
Activity (ADMET) | Neurotoxicity in Mus musculus (mouse) assessed as motor impairment at 30 to 300 mg/kg, ip measured at 0.5 hr by rotarod test | ChEMBL. | No reference | |
Activity (ADMET) | Neurotoxicity in Mus musculus (mouse) assessed as motor impairment at 30 to 300 mg/kg, ip measured at 4 hr by rotarod test | ChEMBL. | No reference | |
Activity (functional) | Anticonvulsant activity in Mus musculus (mouse) assessed as protection against scMET-induced clonic seizures at 30 to 300 mg/kg, ip measured at 0.5 to 4 hr | ChEMBL. | No reference | |
Activity (ADMET) | Neurotoxicity in Mus musculus (mouse) assessed as motor impairment at 100 mg/kg, ip measured at 2 hr by rotarod test relative to control | ChEMBL. | No reference | |
Activity (functional) | Anticonvulsant activity in Mus musculus (mouse) assessed as protection against 6 Hz psychomotor-induced clonic seizures at 100 mg/kg, i.p. measured at 0.5 hr relative to control | ChEMBL. | No reference | |
Activity (functional) | = 50 % | Anticonvulsant activity in Mus musculus (mouse) assessed as protection against 6 Hz psychomotor-induced clonic seizures at 100 mg/kg, i.p. measured at 1 hr relative to control | ChEMBL. | No reference |
MED (functional) | = 100 mg kg-1 | Anticonvulsant activity in i.p. dosed Mus musculus (mouse) assessed as protection against maximal-electric shock-induced seizures measured at 4 hr | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.